The serum levels of prostate specific antigen (PSA) are widely used to screen men for prostate cancer but the well documented lack of sensitivity and specificity has led not only to unnecessary prostate biopsies but also to the limited ability to accurately distinguish patients with or without carcinoma (4). This evidence concerns the gene KLK3 and prostate carcinoma.